Design and optimization of cyclodextrin-based nanosponges of antimalarials using central composite design for dry suspension
Autor: | Sandip Pawar, Pravin Shende |
---|---|
Rok vydání: | 2021 |
Předmět: |
chemistry.chemical_classification
Central composite design Cyclodextrin 010405 organic chemistry Chemistry Nanoporous General Chemistry 010402 general chemistry Condensed Matter Physics 01 natural sciences Controlled release Dosage form 0104 chemical sciences Chemical engineering Chemical stability Particle size Suspension (vehicle) Food Science |
Zdroj: | Journal of Inclusion Phenomena and Macrocyclic Chemistry. 99:169-183 |
ISSN: | 1573-1111 1388-3127 |
DOI: | 10.1007/s10847-020-01038-2 |
Popis: | The hyper cross-linked nanoporous architecture of nanosponges plays a vital role in the development of dosage forms. The innate nature of nanosponges facilitates controlled release profile, chemical stability and taste masking. The current study aimed to synthesize cyclodextrin-based artemether-lumefantrine nanosponges using central composite design as an optimization tool and show their application in the formulation of dry suspension. The cyclodextrins-based nanosponges of artemether-lumefantrine were synthesized using the solvent evaporation method. The optimized nanosponges were characterized by TEM, DSC, XRPD, FTIR, etc. The statistically optimized nanosponge formulation showed a particle size of 335 ± 2.4 nm and percentage entrapment efficiency (% EE) of 69.2 ± 1.6% and 89.6 ± 3.1% for the artemether and lumefantrine, respectively. The formulated suspension was evaluated for taste, sedimentation volume, redispersibility, in-vitro release and chemical stability and exhibited results within acceptable limits. Dry suspension showed a controlled release profile with 89.8 ± 3.2% and 97.7 ± 4.1% release at 24 h for artemether and lumefantrine, respectively. Dry suspension of artemether-lumefantrine-loaded nanosponges presents a contemporary approach and extends their potential in the development of controlled-release suspension of Biopharmaceutical Classification System (BCS) class II and IV drugs. |
Databáze: | OpenAIRE |
Externí odkaz: |